Epilepsy - EISAI

This is a global, postmarketing observational safety study to evaluate the safety and tolerability of Fycompa® (Perampanel) as add-on therapy in epilepsy patients.

For more information, please contact the research team.




Parkinson's Disease - LID

This study is looking at a novel device for the objective assessment of leva-dopa induced dyskinesia.

The aim of this research is to develop a new computer-based system to measure dyskinesia that is simple, reliable and safe to use. During assessment, patients are asked to wear eight small wireless sensors (each limb, head and trunk) that continually monitor the patient's movements.

For more information, please contact the research team.




Multiple Sclerosis - TERI PRO

The purpose of this study is to evaluate overall satisfaction of treatment with teriflunomide including effectiveness, tolerability, convenience, and reduction in disability accumulation from a patient point of view, through the evaluation of the Patient Reported Outcome (PROs) questionnaires in patients with relapsing multiple sclerosis.

The study involves a 54 week treatment programme with fortnightly testing.

For further information, please contact the research team.

 




Epilepsy - EMPIRE study

This study is evaluating the effectiveness and acceptability of dose adjustment strategies of anti-epileptic drugs in patient with epilepsy and pregnancy.

Eligible patients are pregnant women with confirmed diagnosis of epilepsy on lamotrigine (LTG) monotherapy or polytherapy (with carbamazepine CBZ, phenytoin PHT, levetiracetam LEV), CBZ monotherapy, PHT monotherapy and LEV monotherapy. Patients will be followed up every 4-6 weeks from recruitment until delivery. At each follow-up visit, patients will undergo a blood test for serum drug levels, an antenatal check and evaluation of epileptic seizures.

For further information or to recruit a patient to this study, please contact the research team.




Multiple Sclerosis - PASSAGE

A long-term non-interventional study to explore overall safety profile of fingolimod over the long term in patients with relapsing forms of MS under the conditions of routine medical practice.

This trial began in 2013 and recruitment is now complete. The expected end of study date is 2020.

For further information please contact the research team.




Multiple Sclerosis - ToNIC

To develop a bio-psychosocial model of factors affecting quality of life in different neurological conditions- Motor Neurone Disease and Multiple Sclerosis patients at this site.

Inclusion criteria:-

1. Diagnosed with one of the following diseases (first stroke, TBI, MS, NMO, spinal conditions or MND).

2. Adults who are capable of answering questionnaires.

3. Capable of informed consent

4. For interviews, adults with the condition who are able to speak to a researcher, for any people with communication difficulties we will interview people with the assistance of a speech therapist or other support if necessary. For the questionnaire phase, we will not exclude people with difficulty writing due to their neurological condition and allow use of a scribe who records the answer chosen by the participant.

5. Participants wanting to do the qualitative work and cross sectional questionnaire stage can be at any time after diagnosis and participants wanting to do the longitudinal questionnaires commence within one year of diagnosis.

This study asks participants and their carers to complete a comprehensive quality of life questionnaire and is expected to run from 2013 through to 2016.

For further information or to recruit a patient to this study, please contact the research team.




Multiple Sclerosis - ANB study

This is a study to monitor the effectiveness of drug treatments given for MS. Specifically this study looks at the relevance of antibodies to interferon-beta and Copaxone. The findings could help to refine treatment effect so that interferon-beta could be targeted to those whom benefit most.

This trial began recruitment in 2004 and is due to run until 2015. For further information please contact our research team.




Multiple Sclerosis - GAMS

This study is designed to try and identify the genetic factors that are important in multiple sclerosis. Some of these factors influence how likely an individual is to develop the disease while others influence how the disease will affect them or how they will respond to treatment. We believe that identifying these genes will provide valuable insight into the disease and thereby bring us closer to effective treatments and preventative measures.

The trial consists of a short interview and a once only sample of either blood or saliva (for DNA analysis). Recruitment began in 2006 and our site has recruited over 600 participants.

For further information on this study, please contact the research team. 




Multiple Sclerosis - Working with MS

The study consists of two phases: the first phase involved focus group discussions; the second phase is a questionnaire study that will be completed over two and a half years.

The study focuses on the key psychological constructs which influence job retention via focus group discussion in the first instance. In Phase 2 of the study, we aim to measure the identified key psychological factors in a prospective longitudinal study of people with MS in paid employment in West Yorkshire.

The study began in 2013 and 221 patients were recruited.

For further information on this study, please contact the research team.




Huntington's Disease - ENROLL_HD

REGISTRY is the largest Huntington’s disease (HD) study set up to collect valuable clinical data and biological specimens. It helps to understand more about the disease and to work towards finding treatments that can help to either delay or slow down the disease process. It aims to include as many HD-related people as possible.

This study is currently expected to run until 2030.

For further information please contact the research team.




Multiple Sclerosis - MOLGEN

The main aim of the project is to define the genetic and non-genetic risk factors predisposing to adverse drug reactions in order to develop strategies for individualisation of drug therapy to maximise benefits and minimise harms.

The purpose of the study is (a) to identify patients with different types of adverse drug reactions; (b) using blood or saliva samples obtained from these patients, identify genetic factors which predispose to adverse reactions. The net effect of our research will be the development of genetic tests which can help in predicting individual susceptibility to adverse reactions, and thereby prevent through testing before drug intake.

For further information please contact the research team.




Epilepsy - SANAD II

This randomised pragmatic trial aims to compare lamotrigine, levetiracetam and zonisamide as monotherapy in patients with newly diagnosed focal epilepsy (Arm A) and levetiracetam and sodium valproate as monotherapy in newly diagnosed generalised epilepsy (Arm B).

The trial aims to follow up patients for five years collecting information on seizures and any treatment emergent side effects. For further information please contact the research team.




Multiple Sclerosis - EXPAND

BAF312 is a new medicine which is taken as a tablet once a day.

The purpose of this study is to find out if BAF312 is safe and is beneficial in people with Secondary Progressive Multiple Sclerosis (SPMS).

The study will last for two to five years and involves regular visits to the clinic.

Patients in this study will receive either 2mg BAF312 or placebo (no active study drug). The study is double-blind, so neither you nor your study doctor will know which treatment you are receiving (although if your doctor needs to find out he/she can do so).

Approximately 1530 patients from across the world will join this study and approximately 60 of those will be from the UK.

For further information on this study, please contact the research team.




Multiple Sclerosis - TOWER

This is a double-blind parallel-group placebo-controlled study on the efficacy and safety of teriflunomide as a treatment for patients with relapsing multiple sclerosis.

This study is now closed to recruitment.